Cited by 472Antiplatelet Therapy and Cardiovascular DiseasesPharmacogenetics and Drug MetabolismCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events: A Systematic Review and Meta-analysis

Holmes, Michael V., Perel, Pablo, Shah, Tina, Hingorani, Aroon D., Casas, Juan P.·2011·JAMA

DOI 10.1001/jama.2011.1880

Open this paper in CoChat — free account

Abstract

CONTEXT: The US Food and Drug Administration recently recommended that CYP2C19 genotyping be considered prior to prescribing clopidogrel, but the American Heart Association and American College of Cardiologists have argued evidence is insufficient to support CYP2C19 genotype testing. OBJECTIVE: To appraise evidence on the association of CYP2C19 genotype and clopidogrel response through systematic review and meta-analysis. DATA SOURCES: PubMed and EMBASE from their inception to October 2011. STUDY SELECTION: Studies that reported clopidogrel metabolism, platelet reactivity or clinically relevant outcomes (cardiovascular disease [CVD] events and bleeding), and information on CYP2C19 genotype were included. DATA EXTRACTION: We extracted information on study design, genotyping, and disease outcomes and investigated sources of bias. RESULTS: We retrieved 32 studies of 42,016 patients reporting 3545 CVD events, 579 stent thromboses, and 1413 bleeding events. Six studies were randomized trials ("effect-modification" design) and the remaining 26 reported individuals exposed to clopidogrel ("treatment-only" design). In treatment-only analysis, individuals with 1 or more CYP2C19 alleles associated with lower enzyme activity had lower levels of active clopidogrel metabolites, less platelet inhibition, lower risk of bleeding (relative risk [RR], 0.84; 95% CI, 0.75-0.94; absolute risk reduction of 5-8 events per 1000 individuals), and higher risk of CVD events (RR, 1.18; 95% CI, 1.09-1.28; absolute risk increase of 8-12 events per 1000 individuals). However, there was evidence of small-study bias (Harbord test P = .001). When analyses were restricted to studies with 200 or more events, the point estimate was attenuated (RR, 0.97; 95% CI, 0.86-1.09). In effect-modification studies, CYP2C19 genotype was not associated with modification of the effect of clopidogrel on CVD end points or bleeding (P > .05 for interaction for both). Other limitations included selective outcome reporting and potential for genotype misclassification due to problems with the * allele nomenclature for cytochrome enzymes. CONCLUSION: Although there was an association between the CYP2C19 genotype and clopidogrel responsiveness, overall there was no significant association of genotype with cardiovascular events.

Integrity signals

Registry

Crossref · 10.1001/jama.2011.1880

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,819
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W. L., D, E. B. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,496
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102

Flagged first, then by citations

Show all 70 references

Sorted by citations

Items 201–300 of 472

Receptor Inhibitors in Acute Coronary Syndromes: What Is New on the Horizon?
Oprea, A. D., & Popescu, W. M. (2013) · Cardiology Research and Practice · doi:10.1155/2013/195456 · Cited by 16
Impact of CYP2C19 Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary Intervention
Desai, N. R., Canestaro, W. J., Kyrychenko, P., Chaplin, D., Martell, L. A., Brennan, T. A., Matlin, O. S., & Choudhry, N. K. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000321 · Cited by 15
“However, several pharmacogenetic analyses of clopidogrel have not found a significant association between CYP2C19 genotype and clinical outcomes.(8,9) However, the US Food and Drug Administration (FDA) advised avoiding the use of clopidogrel in patients with impaired CYP2C19 function because of known genetic polymorph…”
Background
Aspirin plus ticagrelor or clopidogrel on graft patency one year after coronary bypass grafting: a single-center, randomized, controlled trial
Tang, Y., Fan, X., Zhang, B., Zhang, J., Xue, Q., Xu, Z., & Han, L. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-3407 · Cited by 15
“However, a large meta-analysis suggested an association between the CYP2C19 genotype and clopidogrel responsiveness, but there was no significant association of genotype with cardiovascular events (11).”
Background
High On-Treatment Platelet Reactivity as Predictor of Long-term Clinical Outcomes in Stroke Patients with Antiplatelet Agents
Lv, H., Yang, Z., Wu, H., Liu, M., Mao, X., Liu, X., Ding, H., Shi, Z., Zhou, Y., Liu, Q., et al. (2021) · Translational Stroke Research · doi:10.1007/s12975-021-00949-7 · Cited by 15
Does i-T744C P2Y12 Polymorphism Modulate Clopidogrel Response among Moroccan Acute Coronary Syndromes Patients?
Idrissi, H. H., Hmimech, W., Khorb, N. E., Akoudad, H., Habbal, R., & Nadifi, S. (2017) · Genetics Research International · doi:10.1155/2017/9532471 · Cited by 15
Gene variants in responsiveness to clopidogrel have no impact on clinical outcomes in Chinese patients undergoing percutaneous coronary intervention — A multicenter study
Li, C., Zhang, L., Wang, H., Li, S., Zhang, Y., You, L., Sun, Y., Wang, D., Yang, J., Cui, Y., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.015 · Cited by 15
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes
Povsic, T. J., Ohman, E. M., Roe, M. T., White, J. A., Rockhold, F. W., Montalescot, G., Cornel, J. H., Nicolau, J. C., Steg, P. G., James, S. K., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.1510 · Cited by 15
Evaluation of two Japanese regulatory actions using medical information databases: a ‘Dear Doctor’ letter to restrict oseltamivir use in teenagers, and label change caution against co-administration of omeprazole with clopidogrel
Hanatani, T., Sai, K., Tohkin, M., Segawa, K., Antoku, Y., Nakashima, N., Yokoi, H., Ohe, K., Kimura, M., Hori, K., et al. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12153 · Cited by 14
Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin
Karaźniewicz‐Łada, M., Krzyżańska, D., Danielak, D., Rzeźniczak, J., Główka, F. K., Słomczyński, M., & Burchardt, P. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02822-x · Cited by 14
Cardiovascular Pharmacogenomics: The Future of Cardiovascular Therapeutics?
Roden, D. M. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.07.845 · Cited by 14
Association between CYP2C19*2/*3 Polymorphisms and Coronary Heart Disease
Zhang, Y., Zhou, X., Ji, W., Liu, T., Ma, J., Zhang, Y., & Li, Y. (2019) · Current Medical Science · doi:10.1007/s11596-019-1998-2 · Cited by 14
Pharmacogenomics of Oral Antiplatelet Drugs
Yasmina, A., de Boer, A., Klungel, O. H., & Deneer, V. H. M. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.16 · Cited by 13
Pharmacogenetic Risk Stratification in Angiotensin-Converting Enzyme Inhibitor-Treated Patients with Congestive Heart Failure: A Retrospective Cohort Study
Nelveg-Kristensen, K. E., Madsen, M. B., Torp-Pedersen, C. T., Køber, L., Egfjord, M., Rasmussen, H. B., & Hansen, P. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144195 · Cited by 13
Pharmacogenetics in Cardiovascular Medicine
Tuteja, S., & Limdi, N. A. (2016) · Current Genetic Medicine Reports · doi:10.1007/s40142-016-0096-z · Cited by 13
“03) [17].”
Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance
Siasos, G., Oikonomou, E. K., Vavuranakis, M., Kokkou, E., Mourouzis, K., Tsalamandris, S., Zaromitidou, M., Kioufis, S., Tsigkou, V., Deftereos, S. G., et al. (2017) · Cardiology · doi:10.1159/000457947 · Cited by 13
Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with CYP2C19 polymorphisms: a systematic review
Huang, S., Yang, S., Ly, S., Yoo, R. H., Lo‐Ciganic, W., Eadon, M. T., Schleyer, T., Whipple, E. C., & Nguyen, K. A. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03346-7 · Cited by 13
Summary of the European Society of Cardiology guidelines on dual antiplatelet therapy in patients after percutaneous coronary interventions
Hudzik, B., Błachut, A., Lesiak, M., Kubica, J., Wojakowski, W., & Gąsior, M. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0198 · Cited by 18
Patients with both CYP2C19 loss-of-function allele and peripheral endothelial dysfunction are significantly correlated with adverse cardiovascular events following coronary stent implantation
Tabata, N., Hokimoto, S., Akasaka, T., Arima, Y., Sakamoto, K., Yamamoto, E., Tsujita, K., Izumiya, Y., Yamamuro, M., Kojima, S., et al. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.03.010 · Cited by 13
“Although there is still some controversy regarding this [27], we had clarified that possession of CYP2C19 LOF is associated with adverse clinical events in Japanese patients [6,12], and that some clinical risk factors such as diabetes and chronic kidney disease might modify the effect of CYP2C19 LOF on clinical outcom…”
Background
The Prognostic Value of Combinations of Genetic Polymorphisms in the ITGB3, ITGA2, and CYP2C19*2 Genes in Predicting Cardiovascular Outcomes After Coronary Bypass Grafting
Grinshtein, Y. I., Александровна, К. А., Grinshtein, Y. I., Subbotina, T. N., & Савченко, А. А. (2018) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2017.0177 · Cited by 13
Influences of Corydalis decumbens on the Activities of CYP450 Enzymes in Rats with a Cocktail Approach
Cheng, C., Qian, J., Wang, Z., Li, W., Huang, C., Chen, M., Dong, Y., Lian, L., & Sun, W. (2019) · BioMed Research International · doi:10.1155/2019/9614781 · Cited by 13
“Clopidogrel is metabolized by cytochrome P450 enzymes CYP2C19 [45].”
Background
Distribution of CYP2C19, ABCB1 and PON1 polymorphisms in Chinese Han, Hui, Uygur and Kazak patients with coronary atherosclerotic heart disease
Ma, L., Yuan, Y., Li, J., Yu, C., & Zhao, J. Y. (2020) · International Journal of Immunogenetics · doi:10.1111/iji.12511 · Cited by 13
Implementing high‐dimensional propensity score principles to improve confounder adjustment in UK electronic health records
Tazare, J., Smeeth, L. L., Evans, S. J. W., Williamson, E., & Douglas, I. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5121 · Cited by 12
“In addition, unconfounded studies based on genetic instrumental variable approaches using genetic effects on drug metabolism pathways also suggested no evidence of increased risk.(26) A randomised double-blind trial has TABLE 1 Summary of dimensions for UK electronic health recordss”
Background
The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel
Tousoulis, D., Siasos, G., Zaromitidou, M., Oikonomou, E. K., Maniatis, K., Kioufis, S., Kokkou, E., Papavassiliou, A. G., & Stefanadis, C. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.01.040 · Cited by 13
Genetic Determinations of Variable Responsiveness to Clopidogrel and Implications for Neurointerventional Procedures
Colley, R., & Yan, B. (2012) · Interventional Neurology · doi:10.1159/000338359 · Cited by 13
Expert reviews Significance of antiplatelet therapy in emergency myocardial infarction treatment
Komosa, A., Lesiak, M., Siniawski, A., Mularek‐Kubzdela, T., & Grajek, S. (2014) · Advances in Interventional Cardiology · doi:10.5114/pwki.2014.41466 · Cited by 13
From Hot Hands to Declining Effects
Lauer, M. S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.048 · Cited by 12
Pharmacogenetics in Cardiovascular Disease: The Challenge of Moving From Promise to Realization
Joseph, P. G., Paré, G., Ross, S. A., Roberts, R., & Anand, S. S. (2013) · Clinical Cardiology · doi:10.1002/clc.22200 · Cited by 12
ADP Receptor Antagonists
Cattaneo, M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387837-3.00054-7 · Cited by 12
CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have no Effect on the Antiplatelet Action of Clopidogrel
El-Halabi, M. M., Zgheib, N. K., Mansour, N., Malli, A. H., Ghaith, O. A., Mahfouz, R. A., Alam, S., & Sharara, A. I. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31828ecf44 · Cited by 12
“Two recent meta-analyses showed that there currently is no sufficiently robust or consistent evidence that CYP2C19 genetic polymorphism modifies the clinical efficacy of clopidogrel or increases CV events.(21,22) Holmes et al(22) went even further to say that all studies that showed a significant association between C…”
Background
The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention
Ayesh, B. M., Al-Astal, I. R., & Yassin, M. M. (2019) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-018-00782-3 · Cited by 12
Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta‐analysis of randomized clinical trials
Kheiri, B., Abdalla, A., Osman, M., Barbarawi, M., Zayed, Y., Haykal, T., Chahine, A., Bachuwa, G. I., Hassan, M., & Bhatt, D. L. (2019) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.28075 · Cited by 11
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters
Arbitrio, M., Scionti, F., Martino, M. T. D., Pensabene, L., Tassone, P., & Tagliaferri, P. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00013-x · Cited by 12
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks
Singh, M., Bhatt, D. L., Stone, G. W., Rihal, C. S., Gersh, B. J., Lennon, R. J., Narula, J., & Fuster, V. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.06.013 · Cited by 11
“Although an association between CYP2C19 genotype variability and clopidogrel responsiveness has been reported, a consistent association between genotype and cardiovascular events has not been demonstrated.(38,39) Genetic analysis from CHARISMA and CURE trials did not show a major clinical impact of reduced function al…”
Background
CYP2C19 Genotype and Cardiovascular Events
Tousoulis, D. (2012) · JAMA · doi:10.1001/jama.2012.445 · Cited by 12
Single-Variant and Multi-Variant Trend Tests for Genetic Association with Next-Generation Sequencing That Are Robust to Sequencing Error
Kim, W., Londoño, D., Zhou, L., Xing, J., Nato, A. Q., Musolf, A. M., Matise, T. C., Finch, S. J., & Gordon, D. (2012) · Human Heredity · doi:10.1159/000346824 · Cited by 11
Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation
Chen, H., Power, D., & Giustino, G. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1523718 · Cited by 11
Principles of Pharmacogenomics
Lam, Y. W. F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812626-4.00001-2 · Cited by 15
Use of genetic data to guide therapy in arterial disease
Ross, S. A., Nejat, S., & Paré, G. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12924 · Cited by 11
Treatment Options for Patients With Poor Clopidogrel Response
Roberts, D. I., & Nawarskas, J. J. (2013) · Cardiology in Review · doi:10.1097/crd.0b013e3182a72fab · Cited by 11
Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults
Thatte, U. M., Sridharan, K., Kataria, R., Tolani, D., Bendkhale, S. R., & Gogtay, N. (2016) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.186191 · Cited by 11
“[1] Furthermore, clopidogrel is a prodrug depending on CYP2C19 for conversion to an active metabolite, 2‐oxo‐clopidogrel.[2] Polymorphisms in CYP2C19 (*1, *2, and *3) have been shown to affect antiplatelet response of clopidogrel in various studies.”
Background
Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel – proton pump inhibitor interaction
Kruik‐Kollöffel, W. J., van der Palen, J. A. M., Kruik, H. J., van Herk‐Sukel, M. P. P., & Movig, K. L. L. (2016) · Pharmacology Research & Perspectives · doi:10.1002/prp2.242 · Cited by 11
“…treated with clopidogrel, carriers of a reduced-function CYP2C19 allele had significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of major adverse CV events, including stent thrombosis, than did noncarriers (Holmes et al. 2011).”
Background
Genetic Polymorphism of CYP2C19 in Pakistani Population.
Riaz, S., Din, S. M., Tareen, U., Tariq, F. A., Latif, Y., Siddiqi, S., Sultan, A., & Mansoor, A. (2019) · PubMed Central · doi:10.22037/ijpr.2019.1100644 · Cited by 11
Pharmacogenomics of Anti-platelet and Anti-coagulation Therapy
Fisch, A. S., Tise, C. G., Stephens, S. H., Horenstein, R. B., & Shuldiner, A. R. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0381-3 · Cited by 11
“By contrast, a recent meta-analysis by Holmes and coworkers [76] concluded that CYP2C19 LOF variants are not clinically significant contributors to clopidogrel response, citing issues with “treatment only” study designs and small study bias as the reasons for positive findings of other meta-analyses.”
Result
Principles of Pharmacogenomics
Lam, Y. W. F., & Cavallari, L. H. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-391918-2.00001-9 · Cited by 11
Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI
Liu, J., Qin, L., Xi, S., Tong, W., Yuan, M., Li, P., Liu, J., Wang, X., Zhang, Y., & Yin, T. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.05.004 · Cited by 10
Translation of Genetics Research to Clinical Medicine
Puggal, M. A., Schully, S. D., Srinivas, P. R., Papanicolaou, G., Jaquish, C. E., & Fabsitz, R. R. (2013) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.113.000227 · Cited by 10
“ourselves spending money on technology with little benefit in the clinical setting.(15) (4) Larger sample numbers are required”
Background
CYP2C19*17increases clopidogrel‐mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel
Pedersen, R. S., Nielsen, F., Stage, T. B., Vinholt, P. J., el Achwah, A. B., Damkier, P., & Brøsen, K. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12297 · Cited by 10
Suboptimal response to clopidogrel: A genetic risk factor for recurrent ischaemic stroke
Bennett, D., & Yan, B. (2013) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2012.09.027 · Cited by 10
The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients
Tang, N., Yin, S., Sun, Z., Xu, X., & Qin, J. (2015) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2014.993696 · Cited by 10
“However the infl uence of the CYP2C19 genotype on clinical outcomes after PCI in clopidogrel-treated patients was not supported in a recent multi-center study [14] and systematic review [15].”
Background
Genetics of Response to Antiplatelet Therapy
Thomas, M. R., & Storey, R. F. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-386930-2.00006-9 · Cited by 10
Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assays
Danielak, D., Komosa, A., Tomczak, A., Graczyk‐Szuster, A., Lesiak, M., Główka, F. K., & Karaźniewicz‐Łada, M. (2017) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2017.1286686 · Cited by 10
“CYP2C19 genotype is most widely recognized as associated with significant risk of adverse clinical events and lower responsiveness to clopidogrel [37,38].”
Background
Discovery of Novel N-Glycoside and Non-Glycoside hSGLT2 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Chang, C.-Y., Ho, Y., Lin, S., & Liu, H. (2019) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2019.93009 · Cited by 10
“Therefore, CYP2C19 inhibitors should be carefully used while cooperating with drugs that affect platelet aggregation [62].”
Background
Pharmacogenomics, concepts for the future of perioperative medicine and pain management: A review
Kaye, A. D., Koress, C. M., Novitch, M. B., Jung, J. W., Urits, I., Viswanath, O., Renschler, J. S., Alpaugh, E. S., & Cornett, E. M. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.07.004 · Cited by 10
Pharmacogenetics of Clopidogrel and Warfarin in the Treatment of Cardiovascular Diseases: An Overview of Reviews
de Lara, D. V., de Melo, D. O., Silva, L. C. A., Gonçalves, T. S., & Santos, P. C. J. L. (2022) · Pharmacogenomics · doi:10.2217/pgs-2021-0158 · Cited by 10
Predictive Ability of Direct-to-Consumer Pharmacogenetic Testing: When is Lack of Evidence Really lack of Evidence?
Kalf, R. R. J., Bakker, R., & Janssens, A. C. J. W. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.8 · Cited by 10
Pharmacogenetics in Cardiovascular Medicine
Weeke, P. E. (2018) · Advances in pharmacology · doi:10.1016/bs.apha.2018.04.002 · Cited by 10
“…find- ings on loss-of-functionCYP2C19 alleles, clopidogrel, and in-stent thrombo- sis compared with the more conflicting findings regarding loss-of-function alleles in CYP2C19, clopidogrel, and MACE among patients with medically managed CAD support this hypothesis (Holmes et al., 2011).”
East Asian perspective on the interaction between proton pump inhibitors and clopidogrel
Zou, D., & Goh, K. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13712 · Cited by 10
CYP2C19 variability and clinical outcomes of clopidogrel, proton pump inhibitors, and voriconazole in Southeast Asia: a systematic review and meta-analysis
Hardi, H., Barinda, A. J., Mahata, L. E., & Fitrianti, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572886 · Cited by 9
The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration
Kim, H.-S., Cho, D., Park, B., Bae, S., Yoon, Y., Oh, M., Ghim, J., Kim, E., Kim, D., & Shin, J. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.225 · Cited by 9
“In this study, we confirmed thatCYP2C19 LOF alleles reduce the active metabolite formation and antiplatelet effects of clopidogrel.(11,19) And, we found the new finding that CYP2C19 PM and IM genotypes exhibited delayed time to MPA after a clopidogrel loading dose, and the antiplatelet effects of clopidogrel decreased…”
Background
Pharmacogenetics of Stroke
Ross, S. A., & Paré, G. (2018) · Stroke · doi:10.1161/strokeaha.118.020369 · Cited by 10
Prevalence of CYP2C19 and ITGB3 polymorphisms among Bangladeshi patients who underwent percutaneous coronary intervention
Islam, M. R., Nova, T. T., Momenuzzaman, N., Rabbi, S. N. I., Jahan, I., Binder, T. M., Islam, M. S., Hasnat, A., & Nahar, Z. (2021) · SAGE Open Medicine · doi:10.1177/20503121211042209 · Cited by 9
Combined Antiplatelet Therapy: Still a Sweeping Combination in Cardiology
Manolis, A. S., Manolis, T. A., Papadimitriou, P., Koulouris, S., & Melita, H. (2013) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525711311020009 · Cited by 9
Personalised antiplatelet treatment: a RAPIDly moving target
Beitelshees, A. L. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60431-0 · Cited by 9
Clinical Application of Pharmacogenetics: Where are We Now?
Rh, V. S. (2013) · PubMed Central · Cited by 9
Advances in the Pharmacogenomics of Antiplatelet Therapy
Akhtar, T., Bandyopadhyay, D., Ghosh, R. K., Aronow, W. S., Lavie, C. J., & Yadav, N. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001013 · Cited by 9
Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care
Rothenbacher, D., Hoffmann, M. M., Breitling, L. P., Rajman, I., Köenig, W., & Brenner, H. (2013) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-13-61 · Cited by 9
“This is in line with the results of a metaanalysis of Holmes and colleagues (11) who compared individuals with any copy of CYP2C19 genetic variants (alleles *2 through *8); presumably, the vast majority of subjects carried a heterozygous genotype.”
Result
Future clinical applications of genomics for acute respiratory distress syndrome
Meyer, N. J. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70134-6 · Cited by 9
Pharmacogenomics in Papua New Guineans
Tucci, J. D., Pumuye, P. P., Helsby, N. A., Barratt, D. T., Pokeya, P., Hombhanje, F. W., & Somogyi, A. A. (2018) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000335 · Cited by 9
Personalized Genomes and Cardiovascular DiseasePreprint
Musunuru, K. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014068 · Cited by 9
“In contrast, other meta-analyses that included studies with lower-risk patients did not find significant relationships between CYP2C19 genotype and clinical events (Bauer et al. 2011; Holmes et al. 2011).”
Result
Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes
Sorich, M. J., Rowland, A., & Wiese, M. D. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098613520030 · Cited by 10
“However, due to differences in definition of bleeding events between trials and significant heterogeneity between study results the relationship remains unclear [Holmes et al. 2011; Sorich et al. 2012].”
Background
Measured Drug Effect and Cardiovascular Outcomes in Patients Receiving Platelet P2Y12Receptor Antagonists
Price, M. J. (2012) · JAMA · doi:10.1001/jama.2012.34011 · Cited by 9
From polygenic risk to digital twins: the future of personalised cardiovascular medicine
Antoun, I., Alkhayer, A., Abdelrazik, A., Eldesouky, M., Thu, K. M., Ibrahim, M. N., Dhutia, H., Somani, R., & Ng, G. A. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1735094 · Cited by 8
Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention
Cavallari, L. H. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1355236 · Cited by 8
Current Status of Clopidogrel Pharmacogenomics
Giusti, B., Gori, A. M., Marcucci, R., & Abbate, R. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.153 · Cited by 8
Net clinical benefit of clopidogrel versus ticagrelor in elderly patients carrying CYP2C19 loss-of-function variants with acute coronary syndrome after percutaneous coronary intervention
Zhang, D., Li, P., Qiu, M., Liang, Z., He, J., Li, Y., & Han, Y. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117395 · Cited by 8
Roles of CYP2C19 Gene Polymorphisms in Susceptibility to POAG and Individual Differences in Drug Treatment Response
Liu, X.-L., Jia, Q.-J., Wang, L., Liu, Z., Liu, H., Duan, X., & Lyu, X. (2016) · Medical Science Monitor · doi:10.12659/msm.894868 · Cited by 8
“Owing to the drug metabolic enzymes, treatment of POAG using timolol is improved; however, patients carrying different CYP2C19 phenotypes may differ in drug response [24].”
Background
Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis
Wang, X., Wang, S., Yang, J., Yu, X., & Liu, L. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.06.002 · Cited by 8
Pharmacogenomics of antiplatelet drugs
Sabatine, M. S., & Mega, J. L. (2014) · Hematology · doi:10.1182/asheducation-2014.1.343 · Cited by 7
Nanotechnologies in preventive and regenerative medicine: Quo Vadis, Domine ?
Uskoković, V., & Uskokovic, D. P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48063-5.00012-5 · Cited by 7
The Effect of CYP2C19 Genotype-Guided Antiplatelet Therapy on Outcomes of Selective Percutaneous Coronary Intervention Patients: An Observational Study
Tan, K., Lian, Z., Shi, Y., Wang, X., Yu, H., Li, M., Tian, J., & Ge, Y. (2019) · Personalized Medicine · doi:10.2217/pme-2018-0087 · Cited by 7
Effects of mongolian medicine Terminalia chebula Retz. on 6 CYP450 enzymes in rats.
Wu, G., Dong, Z., Dong, J., Wei, L., Shi, R., Kang, S., & Zhang, D. (2020) · Europe PMC (PubMed Central) · Cited by 7
Complementary medicines used in ulcerative colitis and unintended interactions with cytochrome P450-dependent drug-metabolizing enzymes
Şen, A. (2022) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5482 · Cited by 8
Thrombozytenfunktion – neue Medikamente, neue Assays
Mahla, E., Höchtl, T., Prüller, F., Freynhofer, M. K., & Huber, K. (2012) · Der Anaesthesist · doi:10.1007/s00101-012-2041-1 · Cited by 7
Indirect Estimation of the Comparative Treatment Effect in Pharmacogenomic Subgroups
Sorich, M. J., Coory, M. D., & Pekarsky, B. A. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072256 · Cited by 7
“The clopidogrel case study is a good example in which the effect of CYP2C19 genotype varies significantly between studies, but the reason for the variation is not well understood [9,10].”
BackgroundMethod
Progressing the utilisation of pharmacogenetics and pharmacogenomics into clinical care
Trent, R. J., Cheong, P. L., Chua, E. W., & Kennedy, M. A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b66e · Cited by 7
Value-Based Assessment of Pharmacodiagnostic Testing from Early Stage Development to Real-World Use
Burns, L. C., Orsini, L. S., & L’Italien, G. (2013) · Value in Health · doi:10.1016/j.jval.2013.06.007 · Cited by 8
“, CYP2 with clopidogrel) [1,2].”
Background
Application of routine electronic health record databases for pharmacogenetic research
Yasmina, A., Deneer, V. H. M., der Zee, A. H. M., van Staa, T. P., de Boer, A., & Klungel, O. H. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12226 · Cited by 7
“…risk of cardiovascular events was found among those on clopidogrel who were poor metab-olizers for CYP2C19, whereas studies that included a non-exposed (control) group did not ﬁnd an interaction between poor metabolizers of CYP2C19 and the effect of clopidogrel on cardiovascular events [61].”
Background
Evaluation of clopidogrel response variability and identification of the CYP2C19 polymorphism in Mexican patients
Viveros, M. E., Areán, C., Gutiérrez, S., Vázquez, S., Cardiel, M. H., Taboada, A., Marín, G., Solorio, R., & García, N. (2016) · Archivos de cardiología de México · doi:10.1016/j.acmx.2016.01.007 · Cited by 7
Pharmacokinetics and relative bioavailability of fixed-dose combination of clopidogrel and aspirin versus coadministration of individual formulations in healthy Korean men
Choi, H., Ghim, J., Shon, J., Choi, Y.-K., & Jung, J. A. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s109080 · Cited by 7
“18 In addition, clopidogrel is mainly metabolized to its active metabolite by CYP2C19, 19 so it is important to consider comedication with drugs having the same metabolic route.”
Influential
Association of CYP2C19*2 Polymorphism with Clopidogrel Response and 1-year Major Adverse Cardiovascular Events in A Multiethnic Population with Drug-Eluting Stents
Tan, S. S. N., Fong, A. Y. Y., Mejin, M., Gerunsin, J., Kong, K. L., Chin, F. Y. Y., Tiong, L. L., Lim, M. S. H., Said, A., Khiew, N. Z., et al. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0078 · Cited by 8
A Randomized Double‐Blind Placebo‐Controlled Trial to Evaluate Prophylactic Effect of Traditional Chinese Medicine Supplementing Qi and Hemostasis Formula on Gastrointestinal Bleeding after Percutaneous Coronary Intervention in Patients at High Risks
Zhang, C., Chaolian, H., Kong, X., Liu, G., Li, N., Liu, J., Zhang, Z., Yang, D., Liang, C.-L., & Wang, J. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/3852196 · Cited by 7
Molecular testing for targeted therapies and pharmacogenomics
Alfaro, M. P., Sepulveda, J. L., & Lyon, E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813776-5.00022-4 · Cited by 7
Point-of-care genetic testing—a new frontier explored
Barrett, P. M., & Topol, E. J. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.63 · Cited by 7
A comparative study of different methods for automatic identification of clopidogrel-induced bleedings in electronic health records.
Lee, H.-J., Jiang, M., Wu, Y., Shaffer, C. M., Cleator, J. H., Friedman, E. A., Lewis, J. P., Roden, D. M., Denny, J. C., & Xu, H. (2017) · PubMed Central · Cited by 7
Personalizing healthcare: from genetics through payment to improving care?
Finlayson, A. E. T., Godman, B., Paterson, K., Aston, E., Haycox, A. R., Gustafsson, L. L., & Ali, R. (2013) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2012.120193 · Cited by 6
Antiplatelet resistance in outpatients with monitored adherence
Walter, P., Tsakiris, D. A., Romanens, M., Arnet, I., & Hersberger, K. E. (2013) · Platelets · doi:10.3109/09537104.2013.845743 · Cited by 6
Risk of ischaemic and haemorrhagic stroke in Chinese undergoing percutaneous coronary intervention treated with potent P2Y12 inhibitor versus clopidogrel
Ng, A. K., Ng, P. Y., Ip, A., Lau, K. K., & Siu, C. (2022) · Stroke and Vascular Neurology · doi:10.1136/svn-2021-001294 · Cited by 6
Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y12 inhibitors
Xi, Z., Wang, Y., Lu, Q., Qiu, H., Gao, Y., Gao, A., & Gao, R. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.05.023 · Cited by 6
Pharmacogenetics in Cardiovascular Diseases
Cavallari, L. H., & Momary, K. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812626-4.00006-1 · Cited by 6
Novel Anti-platelet Agents in Acute Coronary Syndrome: Mechanisms of Action and Opportunities to Tailor Therapy
Quatromoni, N., Tuteja, S., Kolansky, D. M., Matthai, W., & Giri, J. S. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0501-1 · Cited by 6

Authors: Holmes, M. V., Perel, P., Shah, T., Hingorani, A. D., & Casas, J. P.
Affiliations: University College London (GB)
Northwestern University (US)
ORCID: Holmes, Michael V.
Perel, Pablo
Shah, Tina
Hingorani, Aroon D.
Casas, Juan P.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2011-12-28
Volume: 306
Issue: 24
Pages: 2704
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2011.1880
OpenAlex: W2119186881
Cited by: 472
References: 70
Citations by year: 2026: 10 · 2025: 10 · 2024: 7 · 2023: 13 · 2022: 18 · 2021: 22 · 2020: 19 · 2019: 27 · 2018: 23 · 2017: 25 · 2016: 36 · 2015: 46 · 2014: 53 · 2013: 89 · 2012: 70
FWCI: 47.48
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute for Health and Care Research (RP-PG-0407-10314)
British Heart Foundation (FS05/125)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords: CYP2C19 genotype, clopidogrel, clopidogrel response, platelet function, platelet aggregation inhibition, cardiovascular events, bleeding risk, stent thrombosis, genotype testing, pharmacogenetics, small-study bias, effect modification, clopidogrel resistance, clopidogrel hypersensitivity, clopidogrel metabolite
MeSH terms: Clopidogrel, Aryl Hydrocarbon Hydroxylases, Cardiovascular Diseases, Genotype, Hemorrhage, Humans, Platelet Aggregation, Platelet Aggregation Inhibitors, Platelet Function Tests, Risk, Thrombosis, Ticlopidine, Angioplasty, Balloon, Coronary, Randomized Controlled Trials as Topic, Cytochrome P-450 CYP2C19

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events: A Systematic Review and Meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks